How to Get Vyvanse in Wyoming

Who Can Prescribe Vyvanse in Wyoming

Any Wyoming-licensed clinician holding an active DEA Schedule II registration can prescribe lisdexamfetamine. That includes physicians (MD/DO), nurse practitioners with prescriptive authority granted by the Wyoming State Board of Nursing, and physician assistants whose supervising physician has delegated Schedule II prescribing privileges under W.S. 33-26-502.

Wyoming NPs gained full prescriptive authority for controlled substances in 2021, which expanded ADHD treatment access in rural counties where physician density is low. The state averages roughly 5.1 primary care physicians per 10,000 residents, one of the lowest ratios in the U.S. according to HRSA Area Health Resource File data from 2024. NPs and PAs now write a meaningful share of stimulant prescriptions in frontier health professional shortage areas across the state.

Before prescribing, most clinicians perform a structured diagnostic evaluation. The American Academy of Family Physicians recommends using validated tools such as the Adult ADHD Self-Report Scale (ASRS-v1.1) and obtaining collateral history from a family member or partner when possible [1]. Wyoming law does not mandate a specific assessment instrument, but documentation of DSM-5 criteria is the standard medicolegal expectation.

Telehealth Prescribing Rules for Vyvanse in Wyoming

Wyoming permits telehealth prescribing of Schedule II controlled substances. The state adopted its Telemedicine Act under W.S. 33-26-102, and the DEA's 2025 Telemedicine Prescribing Rule extended the flexibility originally granted during the COVID-19 public health emergency.

Under the current DEA framework, a prescriber may issue an initial 30-day supply of a Schedule II stimulant via telehealth without an in-person visit, provided the encounter uses real-time audio-video and meets state-specific documentation standards [2]. Wyoming's Board of Medicine requires that the telehealth encounter produce the same quality of documentation as an in-person visit, including a treatment plan, risk-benefit discussion, and informed consent.

For continuation prescriptions, no in-person visit is required in Wyoming as long as the prescriber maintains an active patient relationship and documents follow-up assessments at intervals consistent with clinical guidelines. The American Professional Society of ADHD and Related Disorders (APSARD) consensus recommends re-evaluation every 3 to 6 months for stable adult patients on stimulant therapy.

Patients in remote Wyoming counties (Sublette, Hot Springs, Niobrara, and others with populations below 5,000) benefit significantly from telehealth access. One study estimated that 68% of Wyoming's geography qualifies as a mental health professional shortage area [3].

What Labs and Evaluations Are Needed Before Starting Vyvanse

No lab test is universally required before prescribing lisdexamfetamine, but clinical guidelines recommend a targeted workup. Baseline evaluations help rule out medical mimics and establish cardiovascular safety.

Cardiovascular screening. The American Heart Association and American Academy of Pediatrics recommend obtaining a personal and family cardiac history before starting any stimulant. A resting heart rate, blood pressure measurement, and targeted cardiac review of systems are standard. An ECG is not routinely required in patients without cardiac risk factors, according to the AHA's 2008 scientific statement reaffirmed in 2023 [4].

Baseline vitals and weight. Lisdexamfetamine can raise resting heart rate by 2 to 6 bpm and systolic blood pressure by 1 to 4 mmHg, as observed in the key Wigal et al. trial (N=414) published in the Journal of Attention Disorders [5]. Tracking weight is especially relevant in adults being treated for binge eating disorder, where mean weight loss of 5.3 kg was reported at 12 weeks in the phase III registration trial [6].

Substance use screening. Because lisdexamfetamine is a prodrug requiring enzymatic cleavage in the GI tract, its abuse liability is lower than immediate-release amphetamine. The Vyvanse FDA label notes a "lower subjective drug-liking score at equivalent doses compared to d-amphetamine" [7]. Clinicians should still screen for active substance use disorders using a validated tool like the DAST-10 or CAGE-AID.

Thyroid function. Hyperthyroidism mimics ADHD symptoms. A TSH level is reasonable when the clinical picture includes weight loss, tremor, or heat intolerance alongside inattention.

Pregnancy testing. For patients of reproductive age, a urine pregnancy test is standard before initiating any amphetamine-class medication. The FDA lists lisdexamfetamine as Category C with limited human data.

Wyoming Medicaid and Insurance Coverage for Vyvanse

Wyoming Medicaid does not cover Vyvanse for ADHD or binge eating disorder. The drug is absent from the Wyoming Department of Health Preferred Drug List as of Q1 2026. Patients enrolled in Wyoming Medicaid who need lisdexamfetamine face two practical paths: appeal through the prior authorization process or switch to a covered alternative.

Covered alternatives on Wyoming Medicaid include generic mixed amphetamine salts (Adderall), generic methylphenidate ER, and generic dextroamphetamine. The Medicaid prior authorization denial rate for non-preferred brand stimulants exceeded 60% nationally in 2024, based on CMS Drug Utilization Review data [8].

Commercial insurance. Most commercial plans in Wyoming (Blue Cross Blue Shield of Wyoming, Cigna, UnitedHealthcare) cover Vyvanse with prior authorization. The typical PA process requires documentation of:

• A confirmed ADHD or binge eating disorder diagnosis
• Failure of, or contraindication to, at least one preferred formulary stimulant
• Clinical notes from the diagnosing encounter
• A treatment plan with measurable goals

Turnaround is 48 to 72 hours for standard requests and 24 hours for urgent requests. Denial rates drop substantially when the prescriber submits chart notes alongside the PA form rather than relying on the pharmacy to initiate the request alone.

Generic lisdexamfetamine. The FDA approved the first generic lisdexamfetamine capsules in August 2023. Average cash price for a 30-day supply of generic lisdexamfetamine 50 mg fell to approximately $90 to $150 at major chain pharmacies by early 2026, compared to $350 to $420 for brand Vyvanse [9]. Patients paying out of pocket should ask their pharmacist to run the generic NDC.

Manufacturer savings. Takeda's Vyvanse savings card reduces the copay to as low as $30 per fill for commercially insured patients. It does not apply to government-funded insurance programs including Medicaid, Medicare Part D, or TRICARE.

How to Transfer a Vyvanse Prescription to Wyoming

DEA regulations prohibit the transfer of Schedule II prescriptions between pharmacies. This is a federal rule, not a Wyoming-specific restriction. If you move to Wyoming from another state, your new Wyoming-licensed prescriber must issue a fresh prescription [10].

The practical workflow: contact a Wyoming-licensed clinician (in-person or via telehealth), bring your prior medical records and prescription history, and have the new provider write a new prescription on a Wyoming pharmacy. Most prescribers will accept records sent via fax or patient portal from your previous provider and schedule a telehealth visit within 7 to 14 days.

Wyoming participates in the Prescription Drug Monitoring Program (PDMP) Interstate Data Sharing Hub (PMPInterConnect), which allows Wyoming prescribers to check your controlled substance history from your previous state. This speeds verification and reduces the likelihood of a redundant diagnostic workup [11].

503A Compounding Pharmacies in Wyoming

Wyoming-licensed 503A compounding pharmacies can prepare lisdexamfetamine formulations under a valid patient-specific prescription. This is relevant for patients who need non-standard dosage forms (oral solutions, lower-dose capsules for titration) or who have allergies to inactive ingredients in the manufactured product.

Wyoming Board of Pharmacy regulations require 503A pharmacies to compound in response to an individual prescription and not in bulk for office use. The pharmacy must source the active pharmaceutical ingredient (API) from an FDA-registered supplier, and the final preparation must comply with USP <795> standards for non-sterile compounding [12].

503A pharmacies located outside Wyoming may ship compounded lisdexamfetamine into the state if they hold a Wyoming non-resident pharmacy license. Patients should verify that the out-of-state pharmacy appears on the Wyoming Board of Pharmacy's active license list before placing an order. Schedule II compounds shipped across state lines must be delivered to the patient's verified address and require a signature on receipt.

Cost varies. A 30-day compounded lisdexamfetamine preparation typically runs $60 to $120, which can undercut even the generic manufactured product depending on dose and pharmacy.

Vyvanse Dosing, Titration, and Monitoring in Wyoming Practice

The FDA-approved starting dose for ADHD in adults is 30 mg once daily in the morning, with titration in 10 mg or 20 mg increments at weekly intervals up to a maximum of 70 mg per day [7]. For binge eating disorder in adults, the target dose is 50 mg to 70 mg daily, initiated at 30 mg.

Wigal et al. (2017) demonstrated that the forced-dose titration design of the key ADHD trial (N=414) produced statistically significant improvement on the ADHD-RS-IV total score at every dose tested (30, 50, and 70 mg) versus placebo, with effect sizes (Cohen's d) of 0.80, 1.10, and 1.28, respectively [5]. The 70 mg dose showed the largest absolute reduction (a mean decrease of 18.6 points vs. 5.2 points for placebo).

"The prodrug mechanism of lisdexamfetamine provides a smoother pharmacokinetic curve compared to immediate-release amphetamine, with a Tmax of approximately 3.5 hours and clinically meaningful duration of action extending 12 to 14 hours in most adults," according to the Vyvanse prescribing information [7].

Monitoring schedule. After initiation, the AAFP recommends follow-up at 2 to 4 weeks, then every 1 to 3 months during the first year, and every 3 to 6 months once stable [1]. Each visit should document blood pressure, heart rate, weight, symptom response, and side effect burden. Wyoming does not impose state-level monitoring requirements beyond the federal PDMP check-in at each prescribing encounter.

Common side effects. In the adult ADHD registration trial, the most frequent adverse events with lisdexamfetamine 70 mg were decreased appetite (27%), insomnia (19%), dry mouth (26%), and headache (12%) [5]. Serious cardiovascular events remain rare. A large retrospective cohort analysis of 150,359 stimulant users published in the New England Journal of Medicine found no significant increase in the risk of serious cardiovascular events (MI, stroke, sudden cardiac death) among adults taking ADHD stimulants (adjusted RR 0.83 to 95% CI 0.72 to 0.96) [13].

Timeline: How Long Until You Receive Vyvanse in Wyoming

The total time from first contact to medication in hand depends on the prescribing pathway.

Telehealth route. Most telehealth platforms schedule an initial ADHD evaluation within 5 to 10 business days. If the clinician prescribes at the first visit, the e-prescription reaches the pharmacy within hours. Pharmacy fill time for a Schedule II stimulant is typically same-day to 48 hours, depending on stock. Total: 7 to 14 days.

In-person route. Scheduling with a psychiatrist or psychiatric NP in Wyoming can take 4 to 12 weeks due to provider scarcity. Primary care physicians with ADHD experience may have shorter wait times (1 to 4 weeks). Total: 2 to 13 weeks.

Prior authorization delay. Add 2 to 5 business days if the insurer requires PA. Ask your prescriber to submit the PA proactively at the time of prescribing rather than waiting for the pharmacy to trigger it.

Pharmacy stock. Lisdexamfetamine supply normalized in late 2024 after the DEA increased the aggregate production quota for amphetamine-class stimulants by 12% for the 2025 production year [14]. Shortages are now uncommon at major chain pharmacies in Cheyenne, Casper, and Laramie. Independent pharmacies in smaller towns may require 24 to 48 hours to order stock.

Prior Authorization Documentation for Vyvanse in Wyoming

The specific documents needed for a successful Vyvanse prior authorization vary by insurer, but a composite list based on the three largest commercial carriers in Wyoming includes:

1. Diagnosis confirmation. ICD-10 code (F90.0, F90.1, or F90.2 for ADHD; F50.81 for binge eating disorder) with the date of diagnostic evaluation.
2. Step therapy evidence. Chart notes showing a trial of at least one preferred formulary medication (typically generic methylphenidate ER or generic mixed amphetamine salts) with documentation of inadequate response, intolerable side effects, or a clinical contraindication.
3. Treatment plan. Stated dose, frequency, duration, and measurable treatment goals (e.g., target ADHD-RS-IV score, binge episode frequency reduction).
4. Prescriber credentials. Active Wyoming license number and DEA registration number.
5. Supporting clinical notes. Progress notes from the two most recent visits are commonly requested on appeal.

"Prior authorization exists to verify medical necessity, but it should not function as an outright barrier to evidence-based treatment. When the clinical documentation is complete, approval rates for stimulants exceed 85%," notes the American Academy of Family Physicians clinical guidance on ADHD pharmacotherapy [1].

Patients denied coverage can file a formal appeal. Wyoming Insurance Department regulations require insurers to respond to internal appeals within 30 days for non-urgent cases and 72 hours for urgent cases. External review through an independent review organization (IRO) is available if the internal appeal is denied.